Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]

November 28, 2014 6:17 AM

3 0

(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1] . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

- LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening the formal review clock by 60 days[2]

Also read: Johnny Manziel Agrees to Treatment ... In Domestic Violence Case

Read more

To category page

Loading...